Rademikibart

乐德奇拜单抗

Report date: 2026/04/30 10:01:28

Base Information

Drug NameRademikibart
Drug Alias NameLedechibaimabCBP-201SIM0718SIM-0718
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicNasal Polyps +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[15] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSuzhou Connect Biopharmaceuticals Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesConnect Biopharm LLCSimcere Pharmaceutical Co LtdSuzhou Connect Biopharmaceuticals Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveStatus Asthmaticus +[4] 
Inactive IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Nasal PolypsSinusitis

Other Information

ATC CodeN/A
Related LinksN/A